Prothena Corp Public vs Voyager Therapeutics
PRTA and VYGR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRTA and VYGR compare
Prothena Corp Public is the larger company, worth 3.9 times as much as Voyager Therapeutics ($419M against $107M).
Prothena Corp Public grew revenue faster over the last twelve months (347% versus −19.8% for Voyager Therapeutics).
Prothena Corp Public keeps more of each dollar of sales as profit, with a net margin of −45.4% compared with −416% at Voyager Therapeutics.
Prothena Corp Public scores higher on the StockData Score (12 against 8 for Voyager Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRTA | VYGR |
|---|---|---|
| Size and price | ||
| Market cap | $419M | $107M |
| Share price | $8.16 | $1.73 |
| Change, 1 year | −24.8% | −59.3% |
| Change, 5 years | −86.1% | −47.4% |
| Beta (5Y) | 0.86 | 1.19 |
| Employees | 67 | 141 |
| StockData Score | ||
| Total score | 12 (better) | 8 |
| Valuation score | 2 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.9× | 4.2× (better) |
| P/B | 1.6× | 0.8× (better) |
| FCF yield | – | −103% |
| Fair value | $9.83 | $2.87 |
| Margin of safety | 17.0% | 39.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 347% (better) | −19.8% |
| Revenue growth, 5Y average | 62.6% (better) | −25.1% |
| Profitability | ||
| Operating margin | −64.6% (better) | −450% |
| Net margin | −45.4% (better) | −416% |
| FCF margin | – | −437% |
| Return on equity | −8.5% (better) | −58.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 23.95 (better) | 6.81 |
| Altman Z-score | 11.36 (better) | −3.91 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.2% | 56.9% |
| Held by insiders | 32.0% | 2.6% |
| Insider net buying, 12 months | $13.1M (better) | −$298K |
| Short interest, % of float | 22.7% | 7.3% |
Go deeper
- PRTA stock overview
- PRTA income statement
- PRTA valuation and score
- VYGR stock overview
- VYGR income statement
- VYGR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.